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Abstract In patients with acute coronary syndromes
(ACS), early therapy with high-dose statins may reduce
short-term adverse clinical outcomes. The mechanisms
responsible are not known but could involve anti-inflam-
matory or anti-thrombotic effects. Compelling evidence
from experimental models and clinical studies suggests that
the interplay between inflammatory and thrombotic sys-
tems, typified by platelet–monocyte and platelet–neutrophil
interactions, might be a key regulator of ischemic vascular
events. The study sought to determine if early, high-dose
administration of the HMG-CoA reductase inhibitor rosu-
vastatin in the setting of ACS exerts beneficial vascular
effects by reducing, and inhibiting biomarkers of thromb-
oinflammation, such as platelet-monocyte and platelet-
neutrophil interactions, and biomarkers of myocardial
necrosis. A total of 54 patients presenting with ACS within
8 h of symptom onset were randomized to rosuvastatin
40 mg or placebo. Rosuvastatin significantly reduced
interactions between platelets and circulating neutrophils
(P = 0.015) and monocytes (P = 0.009) within 24 h. No
significant effects were observed on platelet aggregation or
plasma levels of PF4, sP-selectin, or sCD40L, whereas
significant reductions of RANTES occurred over time in
both treatment groups. Plasma levels of myeloperoxidase
(MPO) declined more rapidly with rosuvastatin therapy
than placebo. In a subset of patients with normal cardiac
necrosis biomarkers at randomization, rosuvastatin therapy
was associated with less myocardial damage as measured
by troponin-I or CK-MB. Early administration of high-dose
statin therapy in patients with ACS appears to improve
biomarkers of inflammation within 8 h, which may trans-
late into fewer ischemic events.
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Introduction
Platelets play a central role in the pathogenesis of acute
coronary syndromes (ACS) and in thrombotic complica-
tions of percutaneous coronary intervention (PCI). Anti-
platelet therapy is a mainstay of the initial management of
patients with non-ST-segment elevation (NSTE)-ACS, ST-
segment elevation myocardial infarction (STEMI), and
those undergoing PCI [1]. However, despite the general use
of anti-platelet agents in ACS, recurrent ischemic events
occur in a substantial number of patients. ACS is accom-
panied by an intense inflammatory response. Compelling
evidence from experimental models and clinical studies
suggests that interplay between the inflammatory and
thrombotic systems might be a key regulator of ischemic
vascular events.
Platelet–leukocyte interactions offer an important mech-
anistic link between the inflammatory and thrombotic
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systems. Activated platelets bind to circulating leukocytes
and recruit them to sites of vascular injury and to thrombus.
Experiments in preclinical models indicate that the interac-
tions contribute to local, downstream, and systemic injury
responses [2]. In both ACS and PCI, high levels of circu-
lating platelet–leukocyte heterotypic aggregates correlate
with markers of myocardial necrosis. Moreover, interven-
tions to block the interactions may reduce ischemic injury.
For example, in the recently reported SELECT-ACS trial,
the P-selectin antagonist inclacumab, which blocks the
ability of platelets to bind to leukocytes [3], reduced cardiac
biomarkers of necrosis (troponin-I and creatine kinase-MB
[CK-MB]) in patients with ACS [4]. Such findings suggest
that interactions between platelets and leukocytes may
contribute to ischemic tissue injury in the setting of ACS.
In this study, we sought to determine if administration of a
high-dose of the 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor (statin) rosuvastatin early in
the setting of ACS would exert beneficial effects by reducing
thromboinflammation, specifically platelet interactions with
monocytes and neutrophils. We selected rosuvastatin
because of its ability to lower inflammatory markers in
addition to low-density lipoprotein (LDL)-cholesterol. In the
JUPITER trial [5], which examined rosuvastatin as primary
prevention in patients with increased levels of high-sensi-
tivity C-reactive protein (hs-CRP), the largest benefit
occurred in subjects who had lowering of both hs-CRP and
LDL-cholesterol levels [6]. Several studies have suggested
that the benefits of high dose statin therapy may begin prior to
any significant blood cholesterol lowering effect [7, 8]. In
these trials, rosuvastatin or atorvastatin reduced peri-proce-
dural cardiac necrosis in stable coronary artery disease and
ACS even when administered less than 24 h prior to the
procedure [9–12].
To provide mechanistic insight into the actions of early,
high dose statin therapy, we enrolled ACS patients who
presented within 8 h of symptom onset and randomized
them to receive a 40 mg dose of rosuvastatin or placebo
and monitored monocyte–platelet and neutrophil–platelet
aggregates, markers of platelet activation and inflamma-
tion, within the first 24 h. Our findings suggest that
administration of high-dose rosuvastatin early in the course
of ACS reduces interactions of platelets with monocytes
and neutrophils within 8 h and thereby exert a beneficial
effect on thromboinflammatory pathways.
Materials and methods
Patients and study design
The early use of rosuvastatin in acute coronary syndromes:
targeting platelet–leukocyte interactions (AVATAR) trial
enrolled patients presenting to the University of Kentucky
hospitals with (1) cardiac ischemia within the last 8 h, (2)
biomarker evidence of cardiac ischemia and/or (3) electro-
cardiographic evidence of cardiac ischemia. At screening,
patients 18–80 years of age had to either not be taking a statin
medication or be on a low dose of a statin (defined as prav-
astatin B40 mg, simvastatin B20 mg, or atorvastatin
B10 mg). Supplemental Table 1 lists additional inclusion
and exclusion criteria.
This was an investigator-initiated trial designed by the
investigators (www.clinicaltrials.gov, trial NCT01241903).
The institutional review board at the University of Ken-
tucky approved the protocol, and all patients provided
written informed consent before entering the trial. Patients
were enrolled in a double-blind manner and were ran-
domized to high-dose rosuvastatin (40 mg) or a placebo
given immediately upon consent. All patients received
rosuvastatin 20 mg after the first hospital day and daily
thereafter for 30 days. Blood was sampled at baseline,
prior to randomization, and at approximately 8 and 24 h
following the initial dose. Study follow-up occurred daily
while in hospital and at 30 days after enrollment. Major
adverse cardiovascular events were collected at 30 days.
Flow cytometry
See supplemental materials for details.
Platelet aggregation
See supplemental materials for details.
Biomarker assays
See supplemental materials for details.
Clinical outcomes
See supplemental materials for details.
Statistical analyses
See supplemental materials for details.
Results
Patient characteristics
From November 29, 2011, through July 24, 2013, 54 patients
were enrolled and 53 received either placebo (n = 26) or a
40 mg dose of rosuvastatin (n = 27) at study entry. One
enrolled patient refused to take the initial dose of study
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medication and was removed from further analysis. Table 1
lists demographic and baseline characteristics of the patients
and Table 2 lists cardiovascular medications that patients
received prior to enrollment and in the 24 h following ran-
domization. No significant differences in demographics or
cardiovascular medication use were noted between the two
groups. Table 3 lists clinical features of the patients. Overall,
37 (70 %) of the subjects had a non-ST-segment elevation
myocardial infarction (NSTEMI) or unstable angina (UA),
and 17 (30 %) of the patients suffered a STEMI. Of the 26
patients randomized to the placebo group, 10 had STEMI and
16 NSTEMI/UA. Of the 27 patients randomized to the
rosuvastatin group, 7 had STEMI and 20 NSTEMI/UA.
Forty six of the patients (86.8 %) underwent PCI while in
hospital. The average time from hospital admission to PCI
was 498 ± 156 min for the placebo group (n = 25) and
429 ± 136 for rosuvastatin group (n = 21; P = 0.744).
42.3 % of the patients in the placebo group and 48 % in the
rosuvastatin group underwent PCI prior to the 8 h blood
draw. No significant differences were observed in clinically
obtained troponin-I levels between the placebo and rosu-
vastatin groups at near baseline or approximately 24 h after
randomization. Additionally, platelet and white blood cell
counts at the time of study enrollment and at 24 h were
similar between the two groups.
Table 1 Baseline characteristics of AVATAR subjects
Placebo Rosuvastatin P value
Demographics
Men 17 (65 %) 16 (59 %) 0.779
Women 9 (35 %) 11 (41 %) 0.779
Age 52.8 (10.7) 57.2 (10.4) 0.142
Caucasian 22 (85 %) 24 (89 %) 0.704
African American 3 (12 %) 3 (11 %) 1.000
Hispanic 1 (3 %) 0 (0 %) 0.491
Cardiovascular History
Hypertension 18 (69 %) 17 (63 %) 0.773
History of smoking 21 (81 %) 23 (85 %) 0.728
Hyperlipidemia 19 (73 %) 19 (70 %) 1.000
Diabetes 5 (19 %) 7 (26 %) 0.745
Family history of CHD 15 (58 %) 14 (52 %) 0.785
Prior MI 9 (35 %) 5 (19 %) 0.224
Cardiovascular
Ejection fraction, (%) 49.5 (10.4) 55.4 (7.9) 0.056
Data are n (%) or mean (SD)
P values for the qualitative variables (sex, race, cardiovascular history) were calculated using Fisher’s Exact test
P values for quantitative variables were calculated with a two-sample t test
CHD coronary heart disease, MI myocardial infarction
Table 2 Baseline and 24 h medications for AVATAR subjects
Placebo Rosuvastatin P value
Medication prior to dosage
Aspirin 24 (92 %) 24 (89 %) 1.000
P2Y12 inhibitor 22 (85 %) 23 (85 %) 1.000
Beta blocker 13 (50 %) 10 (37 %) 0.412
ACE inhibitor 13 (50 %) 7 (26 %) 0.093
GPI 4 (15 %) 3 (11 %) 0.704
Heparin 19 (73 %) 14 (52 %) 0.158
Bivalirudin 0 (0 %) 1 (4 %) 1.000
Medication within 24 h
following dosage
Aspirin 24 (92 %) 26 (96 %) 0.610
P2Y12 inhibitor 25 (96 %) 25 (93 %) 1.000
Beta blocker 17 (65 %) 22 (81 %) 0.224
ACE inhibitor 16 (62 %) 14 (52 %) 0.583
GPI 4 (15 %) 3 (11 %) 0.704
Heparin 19 (73 %) 20 (74 %) 1.000
Bivalirudin 2 (8 %) 1 (4 %) 0.610
Data are n (%) or mean (SD)
P values were calculated using Fisher’s Exact test
GPI glycoprotein IIb/IIIa inhibitor
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Effect of early administration of high-dose rosuvastatin
on the percentage monocytes and neutrophils
with associated platelets
Early administration of high dose rosuvastatin resulted in a
statistically significant reduction in circulating monocyte–
platelet aggregates over the first 24 h (P = 0.0029). At the
time of study enrollment (baseline), the percentage of mono-
cytes with associated platelets was 65.5 ± 6.4 % (mean ±
SEM) in the rosuvastatin group and 49.2 ± 3.6 % in the pla-
cebo group (P = 0.132 after Bonferroni adjustment; Table 4).
At 8 h, a striking 25.3 % absolute reduction in average
monocyte–platelet aggregates occurred with rosuvastatin,
whereas the placebo group had a modest 3.1 % decrease
(P = 0.0039 for difference between doses from baseline to
8 h, Table 4). No further decline occurred at 24 h, when
monocyte–platelet aggregates averaged 40.7 ± 5.6 % with
rosuvastatin and 51.6 ± 6.2 % with placebo (P = 0.0029 for
difference between doses from baseline to 24 h, Table 4).
Figure 1a presents the individual data normalized to baseline
(fold change where 1.0 equals baseline value) and demon-
strates an overall reduction in the proportion of monocytes
with platelets in patients who received early, high dose
rosuvastatin.
Analysis of neutrophil–platelet aggregates demonstrated
a significant lowering in the rosuvastatin group over the first
24 h (P = 0.0145, Table 4). At baseline, 31.7 ± 4.4 % of
the neutrophils had attached platelets in the rosuvastatin
group versus 23.1 ± 3.5 % in the placebo group. At 8 h, the
average percentage of circulating neutrophils with adherent
platelets was markedly lower in the rosuvastatin group at
12.8 ± 2.1 (18.9 % absolute reduction) but only slightly
lower in the placebo group at 18.6 ± 3.9 (4.5 % absolute
reduction) (P = 0.0029 for difference between doses from
baseline to 8 h). Average percentages were similar at 24 h,
when the neutrophil–platelet aggregates were 13.3 ± 2.2 %
in the rosuvastatin group and 18.1 ± 3.9 % in the placebo
group (P = 0.0109 for difference between doses from
baseline to 24 h). Figure 1b displays the fold change in
neutrophil–platelet aggregates relative to baseline.
Table 3 Clinical characteristics of patients
Placebo Rosuvastatin P value
ACS
STEMI 10 (38 %) 7 (22 %) 0.387
NSTEMI/UA 16 (62 %) 20 (78 %) 0.387
Hemogram
Baseline platelet count 231 ± 48 220 ± 54 0.462
24 h platelet count 215 ± 55 195 ± 47 0.234
Baseline WBC 10.1 ± 0.7 9.9 ± 0.7 0.871
24 h WBC 9.4 ± 0.7 9.4 ± 0.7 0.931
Cardiac Necrosis
Baseline troponin 0.45 (0.09–2.60) 0.47 (0.08–3.11) 0.907
Peak troponin 9.14 (0.95–35.37) 6.00 (0.12–36.26) 0.478
Data are presented as n (%), mean ± SD, or median (25th–75th percentile). STEMI, NSTEMI, and unstable angina (UA) were determined by the
attending physician based on ECG and cardiac necrosis biomarker lab results. P values were calculated using Fisher’s Exact Test for qualitative
variables, a two-sample t test for approximately normally distributed quantitative variables, and a Mann–Whitney rank sum test for other
quantitative variables
Table 4 Monocyte–platelet and neutrophil– platelet interactions are decreased significantly following treatment of a high-dose rosuvastatin
Baseline % (SE) P value* 8 h % (SE) P value 24 h % (SE) P value Main finding
Monocyte–platelet
Placebo 49.2 (3.6) 0.132 46.1 (6.4) 0.004 51.6 (6.2) 0.003 0.009
Rosuvastatin 65.5 (6.4) 40.2 (4.6) 40.7 (5.6)
Neutrophil–platelet
Placebo 23.1 (3.5) 0.197 18.6 (3.9) 0.009 18.1 (3.9) 0.033 0.015
Rosuvastatin 31.7 (4.4) 12.8 (2.1) 13.3 (2.2)
* Linear mixed model comparing treatment groups on baseline values, with Bonferroni adjustment
 Linear mixed model comparing treatment groups on the change from baseline, with Bonferroni adjustment
 Linear mixed model comparing treatment groups overall, across all time points
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In addition to the primary analysis, an additional ana-
lysis was performed by type of event at presentation
(NSTEMI/UA and STEMI). In NSTEMI patients, a sig-
nificant difference in platelet-neutrophil aggregates, but not
platelet-monocyte aggregates, occurred at 24 h in the two
groups. STEMI patients had significant difference in the
decline over 24 h in platelet-monocyte aggregates but not
platelet-neutrophil aggregates between the groups (Sup-
plemental Fig. 1 and Supplemental Table 2).
In a subset of patients (n = 37), the total number of
monocyte–platelet and neutrophil–platelet aggregates per
ll of blood was determined (Supplemental Table 3). No
significant differences were observed between the rosu-
vastatin and placebo groups at baseline in the numbers of
monocyte–platelet or neutrophil–platelet aggregates per ll
blood. At 8 h and 24 h after rosuvastatin therapy,
significant declines occurred in the total number of neu-
trophil–platelet aggregates/ll blood (P = 0.0021 and
P = 0.0052 for 8 and 24 h, respectively). A non-significant
trend was observed in monocyte–platelet aggregates/ll
blood (P = 0.0785) in the rosuvastatin group at 24 h. No
significant changes from baseline were observed in the
placebo groups for any aggregate type at 8 or 24 h.
Effect of early high-dose rosuvastatin on platelet
function in patients with ACS
Several studies have suggested that statins influence
platelet activity in vitro, and the effect of rosuvastatin on
leukocyte–platelet aggregates could be the result of inhi-
bition of platelet function. TRAP- and ADP- induced
platelet aggregation was therefore monitored prior to and
Fig. 1 Platelet–monocyte and platelet–neutrophil aggregates in ACS
patients randomized to rosuvastatin or placebo. The fold change from
baseline of monocytes with attached platelets for each subject is
plotted at 8 and 24 h following randomization (a). b displays the fold
change of neutrophils with attached platelets from baseline. Overall
significance between groups over 24 h is indicated in Table 4.
Significance between the groups at time points are indicated by (**).
Statistical significance was ascertained using a linear mixed model
and is indicated in Table 4
Fig. 2 TRAP- or ADP-induced




was measured by light
transmission in PRP in response
to 15 lM TRAP (a) and in
response to 5 lM ADP (b).
Area under the curve values in
the Multiplate assay with TRAP
(c) or ADP (d) as an agonist.
Values are presented as the
mean ± SD for the groups at
the indicated times. Statistical
significance of change from
baseline for each group was
determined using a paired t test
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up to 24 h following randomization to rosuvastatin or
placebo using both light transmission aggregometry (LTA)
and multiple electrode aggregometry (MEA). No signifi-
cant differences in TRAP-induced LTA were observed
between groups, nor were there substantial changes over
time (Fig. 2a). At 24 h, ADP-induced LTA was lower than
baseline in both groups (Fig. 2b), likely due to treatment
with P2Y12 antagonists, but there were no significant dif-
ferences between groups. Similar results were observed
with the MEA assays using TRAP (Fig. 2c) and ADP
(Fig. 2d) as agonists, although the response to ADP was
less apparent in the MEA assay.
The ability to aggregate is one measure of platelet
function. We also examined levels of five biomarkers
(sCD40L, P-selectin, VEGF, Platelet Factor 4 (PF4), and
RANTES), whose concentrations in plasma maybe affected
by platelet activation and secretion. The baseline concen-
trations of sCD40L and RANTES were significantly higher
in both the rosuvastatin and placebo groups in comparison
with healthy controls, and the values of both declined over
24 h with no significant differences between the two
groups (Table 5). There were no significant findings for
VEGF, P-selectin, and PF4.
Effect of early high-dose rosuvastatin on plasma
inflammatory biomarkers in patients with ACS
During vascular inflammation, myeloperoxidase (MPO) is
released from leukocytes, particularly neutrophils. Inter-
actions with platelets may promote the release of MPO
from neutrophils [13], and the decline in neutrophil-asso-
ciated MPO in patients with acute MI correlates with an
increase in circulating leukocyte–platelet aggregates [13,
14]. Importantly, elevated levels of MPO in patients with
chest pain predict ischemic cardiovascular events. We
therefore examined MPO in study subjects and results are
presented in Fig. 3a and Table 6. At baseline, MPO levels
were higher in both groups than in healthy controls. The
rosuvastatin group (P = 0.027), but not the placebo
(P = 0.067), group had a significant decrease from base-
line to 8 h. By 24 h following randomization MPO was
also significantly lower in the placebo group (P = 0.005)
and remained significantly lower from baseline in the
rousuvastatin group (P = 0.015). A similar trend was seen
with CRP (Fig. 3b), which increased from baseline to 8 h
in the placebo group (P = 0.050) but not in the rosuvast-
atin group (P = 0.269). Both groups had significant
increases in plasma CRP 24 h following randomization.
Table 6 presents information on additional inflamma-
tory cytokines. At baseline, the levels of IL-6, ENA-78,
MIP-1b, and NAP2 were significantly higher in one or both
groups than in healthy controls. IL-6 levels significantly
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24 h in the rosuvastatin group. ENA-78 and NAP2
decreased at 8 and 24 h in both groups. MIP-1b remained
relatively unchanged in the placebo group at 8 h, with a
trend towards reduction at 24 h in the rosuvastatin group.
Cardiac necrosis markers in patients with ACS
While no significant differences were observed in baseline
and peak troponin-I levels between the two groups
(Table 3), a post hoc sub-analysis was performed in
patients who presented with values\39 the upper limit of
normal to investigate the effect of rosuvastatin on bio-
markers of cardiac necrosis. A total of 24 subjects met this
criterion (n = 12 in each group). At 8 h, CK-MB levels
were elevated significantly from baseline in the placebo
group (P = 0.007, Fig. 3c) but not in the rosuvastatin
group (P = 0.176). Similarly, there was significant
increase in troponin-I levels in the placebo group
(P = 0.003, Fig. 3d) but not the rosuvastatin group
(P = 0.110). At 24 h troponin-I levels remained signifi-
cantly higher than baseline in the placebo group
(P = 0.037) but had not increased significantly from
baseline in the placebo group (P = 0.084). There were no
major adverse ischemic events during the hospital stay for
any of the enrolled patients. No major bleeding occurred in
any subjects. Within the first 30 days, one subject died due
to recurrent MI, and one suffered a stroke. Both individuals
had been randomized to the placebo group.
Discussion
Previous studies have indicated that statins may exert
protective effects if taken within 24 h prior to PCI in
patients with ACS [15], although the mechanism is not
understood. In the AVATAR study, we demonstrated that
intensive statin therapy may be associated with beneficial
effects within 8 h of administration in patients presenting
Fig. 3 Inflammatory and cardiac necrosis levels in ACS patients
randomized to rosuvastatin or placebo. MPO (a) and CRP (b) levels in
subjects randomized to rosuvastatin (shaded boxes) and placebo (white
boxes) at the indicated time points. A subpopulation of patients with
low baseline values of CK-MB were identified for subsequent car-
diac biomarker analysis. CK-MB levels (c) and troponin-I levels (d).
Boxes represent the IQR with the median represented as a solid
horizontal line within the box. Whiskers show the extent of the data sets.
The dashed lines is the MPO and CRP level in pooled plasma from
healthy donors. Statistical significance of change from baseline for each
group was determined using a Wilcoxon signed rank test. P values of
less than 0.05 are indicated by (*)
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with ACS. Early treatment with rosuvastatin 40 mg low-
ered the percentage of monocytes and neutrophils with
attached platelets within 8 h and was accompanied by a
decline in MPO levels. The changes in monocyte–platelet
and neutrophil–platelet interactions occurred without a
detectable effect of rosuvastatin on platelet aggregation or
soluble levels of P-selectin, CD40L, or PF4. Based on
subgroup analysis, acute administration of rosuvastatin was
associated with reduced biomarkers of cardiac damage
within the first 24 h, as has been reported in other settings
[16]. Previous studies that observed cardiac necrosis
markers following PCI in patients that were pre-loaded
with statin demonstrate an acute benefit of statins. Here, we
demonstrate acute effects of statins on monocyte–platelet
and neutrophil–platelet aggregates in patients presenting
with ACS. These findings are also consistent with reports
that rosuvastatin reduces platelet–leukocyte aggregate
formation in a model of congestive heart failure [17] and
blocks postprandial activation of neutrophils [18], although
both of these studies examined long term effects of statins,
over weeks and did not report immediate effects. The
novelty of our study is the identification of an acute effect
(\24 h) of statin therapy on biomarkers of thromboin-
flammation in the setting of ACS.
Statins work by inhibiting the function of HMG-CoA
reductase, which, in turn, lowers the de novo synthesis of
cholesterol. Rosuvastatin and other members of the class
may have pleiotropic effects that are independent of low-
ering LDL-cholesterol levels. Our findings are consistent
with a rapid mechanism of action independent of LDL-
cholesterol and suggest that the ability of rosuvastatin, and
potentially other statins, to impair platelet–leukocyte
interactions could translate into long-term clinical benefit
on top of that gained by lowering cholesterol. The AVA-
TAR results are consistent with observations in experi-
mental and in vitro models in which HMG-CoA reductase
inhibition attenuated leukocyte–platelet interactions [12,
19]. In vitro, statins reduce the expression of mediators of
heterotypic blood cell interactions, such as sCD40, ICAM,
and E-selectin [20–22]. Additional mechanisms of effect
may include improved endothelial function, decreased
oxidative stress, and inhibition thrombogenic responses not
measured by platelet aggregation to ADP or thrombin [23].
The precise mechanism by which rosuvastatin reduce
platelet-leukocyte interaction remain to be defined. How-
ever, much of the data seems to suggest that leukocytes are
the cellular targets of the statin. This is in agreement with
in vitro studies demonstrating that HMG-CoA reductase
inhibitors block Mac-1 activation in monocytes [24]. This
is particularly relevant since Mac-1 mediates platelet leu-
kocyte adhesion.
The AVATAR results may also reflect differences in
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groups. Although no statistically significant difference was
observed in overall monocyte–platelet and neutrophil–
platelet aggregates at baseline between the two groups,
numerically the average percentage of monocytes and
neutrophils with attached platelets was higher at baseline in
the individuals randomized to rosuvastatin. If these patients
were captured at a different time in the presentation of
ACS, more rapid reduction in aggregates could have
resulted. In that case, we would anticipate that heterotypic
aggregates would continue to decline in the placebo group
at 24 h, but they did not. Most of the inflammatory bio-
markers declined or remain unchanged within the first 24 h
after presentation. The exceptions were IL-6, which was
higher at 24 h in the rosuvastatin group at a time when the
frequency of monocyte–platelet and neutrophil–platelet
aggregates was reduced, and CRP which increased from
baseline at 8 h in the placebo group but not in the rosu-
vastatin group.
In summary, the results of the AVATAR trial indicate
that targeting pathways that link inflammation and throm-
bosis may be a beneficial strategy in patients with ACS.
Although the sample size was too small to identify an effect
on clinical outcomes, when considered with previously
published work that demonstrated a reduction in ischemic
and clinical events with early high dose statins that associ-
ated with reduced biomarkers of cardiac necrosis, our
findings suggest that reducing monocyte–platelet and neu-
trophil–platelet interactions may contribute to the acute
benefit that has been observed. If this is true, high-dose statin
therapy should be administered rapidly, similarly to aspirin
therapy, in patients presenting with ACS to maximize effects
independent of LDL-cholesterol lowering.
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